Table 2

Safety and efficacy of pretreatment oral APT in all patients

CharacteristicsAll patients (n=915)Non-APT (n=716)APTP value*P value†
Total (n=199)SAPT (n=137)DAPT (n=62)
Postoperative haemorrhage
 sICH51 (5.6)44 (6.1)7 (3.5)3 (2.2)4 (6.5)0.1530.114
Recanalisation status
 Successful recanalisation mTICI 2b/3838 (91.6)650 (90.8)188 (94.5)128 (93.4)60 (96.8)0.0970.135
 Complete recanalisation mTICI 3642 (70.2)488 (68.2)154 (77.4)111(81)43 (69.4)0.0120.01
Functional outcome at 3 months
 Excellent outcome (mRS 0–1)382 (41.7)294 (41.1)88 (44.2)53 (38.7)35 (56.5)0.4240.046
 Functional independence (mRS 0–2)473 (51.7)372(52)101 (50.8)62 (45.3)39 (62.9)0.7640.067
 Mortality (mRS 6)160 (17.5)127 (17.7)33 (16.6)30 (21.9)3 (4.8)0.7040.004
  • *P value between non-APT and APT group.

  • †P value between non-APT, SAPT and DAPT group.

  • APT, antiplatelet; DAPT, dual antiplatelet; mRS, modified Rankin score; mTICI, modified treatment in cerebral infarction; SAPT, single antiplatelet; sICH, symptomatic intracranial haemorrhage.